Enhanced patient support services improve patient persistence with multiple sclerosis treatment

References

• National Multiple Sclerosis SocietyWho gets MS?New YorkNational Multiple Sclerosis Society Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspxAccessed March 6, 2014
   Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• CohenBARiveraVMPRISMS: the story of a pivotal clinical trial series in multiple sclerosisCurr Med Res Opin201026482783820121658
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialThe IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet200937497001503151119815268
   PubMed Web of Science ®Google Scholar
• ComiGDe StefanoNFreedmanMSComparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised con trolled trialLancet Neurol2012111334122146409
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to long-term therapies: evidence for actionGeneva, SwitzerlandWorld Health Organization2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.htmlAccessed December 7, 2013
   Google Scholar
• Al-SabbaghABennetRKozmaCDicksonMMeleticheDMedication gaps in disease modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJ Neurol2008255Suppl 2S79
   Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
   PubMed Web of Science ®Google Scholar
• KapposLCornelissePLehrLKuhleJUitdehaagBRelation of long-term exposure to subcutaneous interferon beta-1a with clinical outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS-15 studyMult Scler20121843921865413
   PubMed Web of Science ®Google Scholar
• UitdehaagBConstantinescuCCornelissePImpact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyTher Adv Neurol Disord20114131421339904
   PubMedGoogle Scholar
• JinJSklarGEMin Sen OhVChuen LiSFactors affecting therapeutic compliance: A review from the patient’s perspectiveTher Clin Risk Manag20084126928618728716
   PubMedGoogle Scholar
• MikolDDBarkhofFChangPREGARD study groupComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• JonesJLScheidtDJKaushalRSCarrollCAAssessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosisJ Med Econ201316221322023098539
   PubMedGoogle Scholar
• TanHYuJTabbyDDevriesASingerJClinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort studyMult Scler201016895696320595246
   PubMed Web of Science ®Google Scholar
• PattiFOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherencePatient Prefer Adherence201041920165593
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2010181697720561039
   PubMed Web of Science ®Google Scholar
• ThotaABSipeTAByardGJCollaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysisAm J Prev Med201242552553822516495
   PubMed Web of Science ®Google Scholar
• MartinLRWilliamsSLHaskardKBDimatteoMRThe challenge of patient adherenceTher Clin Risk Manag20051318919918360559
   PubMedGoogle Scholar
• KrebsPProchaskaJORossiJSA meta-analysis of computer-tailored interventions for health behavior changePrev Med2010513–421422120558196
   PubMed Web of Science ®Google Scholar
• BergerBALiangHHudmonKSEvaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosisJ Am Pharm Assoc (2003)200545446647216128502
   PubMed Web of Science ®Google Scholar
• ShatilEMetzerAHorvitzOMillerAHome-based personalized cognitive training in MS patients: a study of adherence and cognitive performanceNeuroRehabilitation201026214315320203380
   PubMed Web of Science ®Google Scholar
• NauDPProportion of Days Covered (PDC) as a Preferred Method of Measuring Medication AdherenceSpringfield, VAPharmacy Quality Alliance2011 Available from: http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdfAccessed March 11, 2013
   Google Scholar